Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for δ/μ opioid receptor agonists and neurokinin-1 receptor antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 12, 2007, Pages 2779-2786

  Yamamoto, Takashi ^a,b   Nair, Padma ^a,b   Davis, Peg ^a,c   Ma, Shou Wu ^a,c   Navratilova, Edita ^a,c   Moye, Sharif ^a,c   Tumati, Suneeta ^a,c   Lai, Josephine ^a,c   Vanderah, Todd W ^a,c   Yamamura, Henry I ^a,c   Porreca, Frank ^a,c   Hruby, Victor J ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b The University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RADIOASSAY; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

ANALGESICS; ANIMALS; CELL LINE; DRUG DESIGN; GUINEA PIGS; HUMANS; ILEUM; LIGANDS; MALE; MICE; MICE, INBRED ICR; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 34250896252     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061369n     Document Type: Article

References (56)

1. Yaksh, T. L. Spinal opiate analgesia: characteristics and principles of action. Pain 1981, 11, 293-346.
2. Hill, R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol. Sci. 2000, 21, 244-246.
3. Kalso, E. Improving opioid effectiveness: from ideas to evidence. Eur. J. Pain 2005, 9, 131-135.
4. Khasabov, S. G.; Rogers, S. D.; Ghilardi, J. R.; Peters, C. M.; Mantyh, P. W.; Simone, D. A. Spinal neurons that possess the substance P receptor are required for the development of central sensitization. J. Neurosci. 2002, 22, 9086-9098.
5. Mantyh, P. W.; Allen, C. J.; Ghilardi, J. R.; Rogers, S. D.; Mantyh, C. R.; Liu, H.; Basbaum, A. I.; Vigna, S. R.; Maggio, J. E. Rapid endocytosis of a G protein coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2622-2626.
6. Moochhala, S. M.; Sawynok, J. Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization. Br. J. Pharmacol. 1984, 82, 381-388.
7. Nichols, M. L.; Allen, B. J.; Rogers, S. D.; Ghilardi, J. R.; Honore, P.; Luger, N. M.; Finke, M. P.; Li, J.; Lappi, D. A.; Simone, D. A.; Mantyh, P. W. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 1999, 286, 1558-1561.
8. King, T.; Gardell, L. R.; Wang, R.; Vardanyan, A.; Ossipov, M. H.; Malan, T. P., Jr.; Vanderah, T. W.; Hunt, S. P.; Hruby, V. J.; Lai, J.; Porreca, F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005, 116 (3), 276-288.
9. King, T.; Ossipov, M. H.; Vanderah, T. W.; Porreca, F.; Lai, J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005, 14 (4), 194-205.
10. Ma, W.; Zheng, W. H.; Kar, S.; Quirion, R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience 2000, 99 (3), 529-539.
11. Powell, K. J.; Quirion, R.; Jhamandas, K. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur. J. Neurosci. 2003, 18 (6), 1572-1583.
12. Misterek, K.; Maszczynska, I.; Dorociak, A.; Gumulka, S. W.; Carr, D. B.; Szyfelbein, S. K.; Lipkowski, A. W. Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin. Life Sci. 1994, 54 (14), 939-944.
13. Gu, G.; Kondo, I.; Hua, X. Y.; Yaksh, T. L. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence. J. Pharmacol. Exp. Ther. 2005, 314 (3), 1362-1369.
14. Hokfelt, T.; Kellereth, J. O.; Nilsson, G. Immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurons. Brain Res. 1975, 100, 235-252.
15. Marchand, J. E.; Kream, R. M. Substance P and Somatostatin levels in rhumatioid arthesis, molecular physiology. In Substance P and Related Peptides: Cellular and Molecular Physiology; New York Academy of Science: New York, 1990; pp 437-438.
16. Kondo, I.; Marvizon, J. C.; Song, B.; Salgado, F.; Codeluppi, S.; Hua, X. Y.; Yaksh, T. L. Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release. J. Neurosci. 2005, 25 (14), 3651-3660.
17. Slaninova, J.; Knapp, R. J.; Wu, J.; Fang, S. N.; Kramer, T.; Hruby, V. J.; Yamamura, H. I. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur. J. Pharmacol. 1991, 200, 195-198.
18. Lee, Y. S.; Agnes, R. S.; Badghisi, H.; Davis, P.; Ma, S. W.; Lai, J.; Porreca, F.; Hruby, V. J. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J. Med. Chem. 2006, 49 (5),-1773-1780.
19. Hruby, V. J.; Agnes, R. S.; Davis, P.; Ma, S. W.; Lee, Y. S.; Vanderah, T. W.; Lai, J.; Porreca, F. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci. 2003, 73 (6), 699-704.
20. Agnes, R. S.; Lee, Y. S.; Davis, P.; Ma, S. W.; Badghisi, H.; Porreca, F.; Lai, J.; Hruby, V. J. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J. Med. Chem. 2006, 49 (10), 2868-2875.
21. Bonney, I. M.; Foran, S. E.; Marchand, J. E.; Lipkowski, A. W.; Carr, D. B. Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur. J. Pharmacol. 2004, 488 (1-3), 91-99.
22. Sakurada, T.; Yuhki, M.; Inoue, M.; Sakurada, C.; Tan-No, K.; Ohba, M.; Kisara, K.; Sakurada, S. Opioid activity of sendide, a tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 1999, 369 (3), 261-266.
23. Kosson, P.; Bonney, I.; Carr, D. B.; Lipkowski, A. W. Endomorphins interact with tachykinin receptors. Peptides 2005, 26 (9), 1667-1669.
24. Gentilucci, L. New Torends in the Development of Opioid Peptide Analogues as Advanced Remedies for pain Relief. Curr. Topics Med. Chem. 2004, 4, 19-38.
25. Rapaka, R. S.; Porreca, F. Development of delta opioid peptides as nonaddicting analgesics. Pharm. Res. 1991, 8 (1), 1-8.
26. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ opioid agonists and antagonists. Expert Opin. Ther. Pat. 1997, 7, 1075-1098.
27. Bilsky, E. J.; Calderon, S. N.; Wang, T.; Bernstein, R. N.; Davis, P.; Hruby, V. J.; McNutt, R. W.; Rothman, R. B.; Rice, K. C.; Porreca, F. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther. 1995, 273, 359-366.
28. Quock, R. M.; Burkey, T. H.; Varga, E.; Hosohata, Y.; Hosohata, K.; Cowell, S. M.; Slate, C. A.; Ehlert, F. J.; Roeske, W. R.; Yamamura, H. I. The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol. Rev. 1999, 51 (3), 503-532.
29. Shimohigashi, Y. Design Principles: Enkephalins With Predictable Mu/Delta Receptor Specificity. NIDA Res. Monogr. 1986, 69, 65-100.
30. Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. J.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipowski, A. W.; Hruby, V. J.; Porreca, F. Antinociceptive Profile of Biphalin, a Dimeric Enkephalin Analog. J. Pharmacol. Exp. Ther. 1993, 265, 1446-1454.
31. Macleod, A. M.; Merchant, K. J.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Swain, C. J.; Baker, R. N-Acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J. Med Chem. 1993, 14, 2044-2045.
32. Cascieri, M. A.; Macleod, A. M.; Underwood, D.; Shiao, L. L.; Ber, E.; Sadowski, S.; Yu, H.; Merchant, K. J.; Swain, C. J.; Strader, C. D.; Fong, T. M. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J. Biol. Chem. 1994, 269 (9), 6587-6591.
33. 2 deduced from two-dimensional 1H-NMR and conformational energy calculations is related to its affinity for NK1-receptor. J. Pept. Sci. 2001, 7 (6), 323-330.
34. 2 as NK1/NK2 ligands. Lett. Pep. Sci. 1999, 6, 255-262.
35. Polt, R.; Porreca, F.; Szabo, L. Z.; Bilsky, E. J.; Davis, P.; Abbruscato, T. J.; Davis, T. P.; Horvath, R.; Yamamura, H. I.; Hruby, V. J. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (15), 7114-7118.
36. Misicka, A.; Lipkowski, A. W.; Horvath, R.; Davis, P.; Kramer, T. H.; Yamamura, H. I.; Hruby, V. J. Topographical requirements for delta opioid ligands: common structural features of dermenkephalin and deltorphin. Life Sci. 1992, 51 (13), 1025-1032.
37. Lord, J. A. H; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977, 207, 495-499.
38. Kiritsy-Roy, J. A.; Chan, S. K.; Iwamoto, E. T. Methionine oxidation enhances opioid activity of an enkephalin analog. Life Sci. 1983, 32 (8), 889-893.
39. Glavin, G. B.; Pinsky, C.; Hall, A. M. Effects of metkephamid (LY127623), a selective delta opioid receptor agonist, on gastric function. Life Sci. 1990, 46 (15), 1075-1079.
40. Burkhardt, C.; Frederickson, R. C.; Pasternak, G. W. Metkephamid (Tyr-D-ala-Gly-Phe-N(Me)Met-NH2), a potent opioid peptide: receptor binding and analgesic properties. Peptides 1982, 3 (5), 869-871.
41. Frederickson, R. C.; Smithwick, E. L.; Shuman, R.; Bemis, K. G. Metkephamid, a systemically active analog of methionine enkephalin with potent opioid alpha-receptor activity. Science 1981, 211, 603-605.
42. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
43. Davis, D. G.; Bax, A. Assignment of complex 1H-NMR spectra via two-dimensional homonuclear Hartmann-Hahn spectroscopy. J. Am Chem. Soc. 1985, 107, 2820-2821.
44. Subramanian, S.; Bax, A. Generation of pure phase NMR subspectra for measurement of homonuclear coupling constants. J. Magn. Reson. 1987, 71, 325-330.
45. Rance, M. Improved techniques for homonuclear rotating-frame and isotropic mixing experiments. J. Magn. Reson. 1987, 74, 557-564.
46. Bax, A.; Davis, D. G. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 1985, 65, 355-360.
47. Marion, D.; Wuthrich, K. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 1983, 113, 967-974.
48. Boyd, N. D.; Kage, R.; Dumas, J. J.; Krause, J. E.; Leeman, S. E. The peptide binding site of the substance P (NK-1) receptor localized by a photoreactive analogue of substance P: presence of a disulfide bond, Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 433-437.
49. Lorenzen, A.; Fuss, M.; Vogt, H.; Schwabe, U. Measurement of guanine nucleotide-binding protein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5′-O-(3-[35S]mio) triphosphate binding. Mol. Pharmacol. 1993, 44 (1),115-123.
50. Porreca, F.; Burks, T. F. Affinity of normorphine for its pharmacologic receptor in the naive and morphine-tolerant guinea-pig isolated ileum. J. Pharmacol. Exp. Ther. 1983, 225 (3), 688-693.
51. Porreca, F.; LoPresti, D; Ward, S. J. Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens. Eur. J. Pharmacol. 1990, 179 (1-2), 129-139.
52. Lipkowski, A. W.; Misicka, A.; Davis, P.; Stropova, D.; Janders, J.; Lachwa, M.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Biological activity of fragments and analogues of the potent dimeric opioid peptide, biphalin. Bioorg. Med. Chem. Lett. 1999, 9 (18), 2763-6.
53. Akiyama, K.; Gee, K. W.; Mosberg, H. I.; Hruby, V. J.; Yamamura, H. I. Characterization of [3H][2-D-{penicillamine,5-D-p}enicillamine]-enkephalin Binding to delta Opiate Receptors in the Rat Brain and Neuroblastoma-Glioma Hybrid Cell Line (NG 108-15), Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2543-2547.
54. Mosberg, H. I.; Hurst, M. R.; Hruby, V. J.; Gee, H. K.; Yamamura, H. I.; Galligan, J. J. Burks, T. F. Bis-Penicillamine Enkephalins Possess Highly Improved Specificity toward delta Receptors Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 5871-5874.
55. Mosberg, H. I.; Hurst, R.; Hruby, V. J.; Gee, K.; Akiyama, K.; Yamamura, H. I.; Galligan, J. J.; Burks, T. F. Cyclic penicillamine containing enkephalin analogs display profound delta receptor selectivities. Life Sci. 1983, 33 (Suppl 1), 447-50.
56. Yamamoto, T.; Nair, P.; Davis, P.; Ma, S-W.; Moye, S.; Largent, T.; Vanderah, T. W.; Lai, J.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Design, Structure-Activity Relationships and Biological Evaluation of Novel Bifunctional C-terminal Modified Peptides for delta/ mu Opioid Receptor Agonists and Neurokinin-1 Receptor Antagonists. American Chemical Society, 232nd National Meeting, San Francisco, CA, Sep. 10-14, 2006; p MEDI-7.